NO963371L - Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det - Google Patents
Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av detInfo
- Publication number
- NO963371L NO963371L NO963371A NO963371A NO963371L NO 963371 L NO963371 L NO 963371L NO 963371 A NO963371 A NO 963371A NO 963371 A NO963371 A NO 963371A NO 963371 L NO963371 L NO 963371L
- Authority
- NO
- Norway
- Prior art keywords
- proteins
- well
- polypeptides
- making
- materials
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Ecology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Hematopoietiske proteiner og polypeptidfragmenter av disse tilveiebringes, heriblant proteiner og polypeptider fra mus og menneske. Videre tilveiebringes DNA-molekyler som koder for disse proteiner og polypeptider, så vel som vektorer og celler som er anvendbare til produksjon av disse. An-tistoffer som bindes til en epitop på proteinene, tilveiebringes også. Proteinene og polypeptidene er anvendbare for in vlvo og ex vivo terapi, og som reagenser for celledyrking og under-skelse av celleproliferasjon og -ut-vikling.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19602594A | 1994-02-14 | 1994-02-14 | |
US20319794A | 1994-02-25 | 1994-02-25 | |
US21520394A | 1994-03-21 | 1994-03-21 | |
US25249194A | 1994-06-01 | 1994-06-01 | |
PCT/US1994/008806 WO1995021920A1 (en) | 1994-02-14 | 1994-08-05 | Hematopoietic protein and materials and methods for making it |
Publications (2)
Publication Number | Publication Date |
---|---|
NO963371D0 NO963371D0 (no) | 1996-08-13 |
NO963371L true NO963371L (no) | 1996-10-11 |
Family
ID=27498094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963371A NO963371L (no) | 1994-02-14 | 1996-08-13 | Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det |
Country Status (17)
Country | Link |
---|---|
US (1) | US5989537A (no) |
EP (1) | EP0745125A1 (no) |
JP (1) | JPH09508797A (no) |
KR (1) | KR100289201B1 (no) |
CN (1) | CN1148408A (no) |
AU (1) | AU691828B2 (no) |
BG (1) | BG63508B1 (no) |
BR (1) | BR9408534A (no) |
CA (1) | CA2183266A1 (no) |
CZ (1) | CZ221496A3 (no) |
FI (1) | FI963185A (no) |
HU (1) | HUT75359A (no) |
NO (1) | NO963371L (no) |
NZ (1) | NZ271230A (no) |
PL (1) | PL178384B1 (no) |
SK (1) | SK100896A3 (no) |
WO (1) | WO1995021920A1 (no) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20002180B (en) * | 1994-03-31 | 2000-07-25 | Amgen Inc | Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation |
US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
TW387940B (en) * | 1995-01-17 | 2000-04-21 | Kirin Brewery | Anti-tpo monodonal antibody |
AU4658596A (en) | 1995-02-03 | 1996-08-21 | G.D. Searle & Co. | Novel c-mpl ligands |
US5696250A (en) * | 1995-02-15 | 1997-12-09 | Amgen Inc. | DNA encoding megakaryocyte growth and development factor analogs |
US5989538A (en) * | 1995-02-15 | 1999-11-23 | Amgen Inc. | Mpl ligand analogs |
TW434021B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions |
TW434020B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
PE7898A1 (es) | 1995-06-07 | 1998-03-05 | Glaxo Group Ltd | Peptidos compuestos que se ligan al receptor de trombopoietina |
US6251864B1 (en) | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
TW497972B (en) * | 1995-06-08 | 2002-08-11 | Kirin Brewery | Stable thrombopoietin (TPO)-containing lyophilized compositions |
US6060052A (en) * | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
US6884419B1 (en) * | 1996-12-23 | 2005-04-26 | Kyowa Hakko Kogyo, Co., Ltd. | hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same |
US20030228666A1 (en) | 1998-06-30 | 2003-12-11 | Daewoong Pharmaceutical Co., Ltd. | Novel human thrombopoietin mutein |
SI2319928T1 (sl) | 1998-10-23 | 2013-08-30 | Kirin-Amgen, Inc. | Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2312223T3 (es) | 1998-12-07 | 2009-02-16 | Zymogenetics, Inc. | Zvegf3 homologo de factor de crecimiento. |
US6776984B1 (en) | 1999-08-20 | 2004-08-17 | George R. Schwartz | Induced regeneration and repair of damaged neurons and nerve axon myelin |
CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
CN100448993C (zh) | 2000-06-30 | 2009-01-07 | 津莫吉尼蒂克斯公司 | 干扰素样蛋白质Zcyto21 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
EP1336846A1 (en) * | 2002-02-13 | 2003-08-20 | Procorde GmbH | Method for generating recombinant human platelets for identifying therapeutic target proteins |
AU2003222043A1 (en) * | 2002-03-18 | 2003-10-08 | National Jewish Medical And Research Center | Method for production of neutrophils and uses therefor |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
DE10227611A1 (de) * | 2002-06-20 | 2004-01-15 | Bionethos Holding Gmbh | Verfahren und Vorrichtung zur Vermehrung und Differenzierung von Zellen in Anwesenheit von Wachstumsfaktoren und einer biologischen Matrix oder Trägerstruktur |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
AU2003276846A1 (en) * | 2002-08-09 | 2004-02-25 | Xencor | Thrombopoiesis-stimulating proteins having reduced immunogenicity |
MXPA05003057A (es) | 2002-09-18 | 2006-04-18 | Johnson & Johnson | Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas. |
US20090048318A1 (en) * | 2003-04-29 | 2009-02-19 | Connie Erickson-Miller | Methods for treating degenerative diseases/injuries |
US20100004302A1 (en) * | 2003-04-29 | 2010-01-07 | Connie Erickson-Miller | Methods for Treating Degenerative Diseases/Injuries |
US20090298179A1 (en) * | 2003-04-29 | 2009-12-03 | Connie Erickson-Miller | Methods For Treating Degenerative Diseases/Injuries |
EP1622609A4 (en) | 2003-04-29 | 2008-09-03 | Smithkline Beecham Corp | METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS |
US20090143453A1 (en) * | 2003-04-29 | 2009-06-04 | Connie Erickson-Miller | Methods for treating degenerative diseases/injuries |
DE602004012424T2 (de) | 2003-08-07 | 2009-04-30 | Zymogenetics, Inc., Seattle | Homogene herstellungen von il-29 |
KR101183875B1 (ko) | 2003-08-28 | 2012-09-27 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 수용체에 결합하는 펩티드 및 화합물 |
US7723295B2 (en) | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
ATE544460T1 (de) | 2003-10-24 | 2012-02-15 | Nora Therapeutics Inc | Zusammensetzungen und verfahren für eine gesunde schwangerschaft |
US8338373B2 (en) * | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
US20090226397A1 (en) * | 2003-10-24 | 2009-09-10 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
DE502004011252D1 (de) | 2003-12-30 | 2010-07-15 | Augustinus Bader | Verwendung des erythropoietins zur regeneration von lebergewebe |
JP2008505928A (ja) | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
BRPI0516969A (pt) * | 2004-10-25 | 2008-09-30 | Cellerant Therapeutics Inc | método de preparar uma composição terapêutica, composição terapêutica, e, método de tratar um paciente humano sofrendo de hematopoiese deficiente |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
WO2007102946A2 (en) | 2006-01-23 | 2007-09-13 | Amgen Inc. | Crystalline polypeptides |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
CA2687141C (en) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
KR101040396B1 (ko) | 2009-01-20 | 2011-06-09 | 한올바이오파마주식회사 | 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5154921A (en) * | 1990-07-13 | 1992-10-13 | Dana-Farber Cancer Institute, Inc. | Promotion of maturation of hematopoietic progenitor cells |
US5571686A (en) * | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
-
1994
- 1994-08-05 KR KR1019960704354A patent/KR100289201B1/ko not_active IP Right Cessation
- 1994-08-05 BR BR9408534A patent/BR9408534A/pt not_active Application Discontinuation
- 1994-08-05 NZ NZ271230A patent/NZ271230A/en unknown
- 1994-08-05 WO PCT/US1994/008806 patent/WO1995021920A1/en not_active Application Discontinuation
- 1994-08-05 EP EP94924579A patent/EP0745125A1/en not_active Withdrawn
- 1994-08-05 CN CN94194997A patent/CN1148408A/zh active Pending
- 1994-08-05 AU AU74810/94A patent/AU691828B2/en not_active Ceased
- 1994-08-05 CZ CZ962214A patent/CZ221496A3/cs unknown
- 1994-08-05 CA CA002183266A patent/CA2183266A1/en not_active Abandoned
- 1994-08-05 PL PL94315914A patent/PL178384B1/pl unknown
- 1994-08-05 JP JP7521187A patent/JPH09508797A/ja active Pending
- 1994-08-05 HU HU9602224A patent/HUT75359A/hu unknown
- 1994-08-05 SK SK1008-96A patent/SK100896A3/sk unknown
-
1995
- 1995-06-07 US US08/484,257 patent/US5989537A/en not_active Expired - Lifetime
-
1996
- 1996-08-06 BG BG100771A patent/BG63508B1/bg unknown
- 1996-08-13 NO NO963371A patent/NO963371L/no not_active Application Discontinuation
- 1996-08-14 FI FI963185A patent/FI963185A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
FI963185A0 (fi) | 1996-08-14 |
PL315914A1 (en) | 1996-12-09 |
FI963185A (fi) | 1996-08-14 |
CN1148408A (zh) | 1997-04-23 |
NZ271230A (en) | 1998-03-25 |
CZ221496A3 (en) | 1997-07-16 |
HU9602224D0 (en) | 1996-10-28 |
BG63508B1 (bg) | 2002-03-29 |
JPH09508797A (ja) | 1997-09-09 |
HUT75359A (en) | 1997-05-28 |
BR9408534A (pt) | 1997-08-05 |
US5989537A (en) | 1999-11-23 |
BG100771A (en) | 1997-08-29 |
SK100896A3 (en) | 1997-10-08 |
NO963371D0 (no) | 1996-08-13 |
AU7481094A (en) | 1995-08-29 |
EP0745125A1 (en) | 1996-12-04 |
WO1995021920A1 (en) | 1995-08-17 |
PL178384B1 (pl) | 2000-04-28 |
KR100289201B1 (ko) | 2001-05-02 |
AU691828B2 (en) | 1998-05-28 |
CA2183266A1 (en) | 1995-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963371L (no) | Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det | |
BRPI0412007A (pt) | mutagênese look-through | |
GEP20022681B (en) | Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth | |
NZ323795A (en) | Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides | |
WO2001053349A3 (en) | Small cell lung cancer associated antigens and uses therefor | |
EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
DE69715621T2 (de) | Drei hybriden screening test | |
BR9809443A (pt) | Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão. | |
NO20014584D0 (no) | Proteinisolering og -analyse | |
DE69535719D1 (de) | Fas-antigenbindender ligand | |
CA2413156A1 (en) | Expression vectors | |
WO2000020587A3 (en) | Cancer associated antigens and uses therefor | |
WO2004024750A3 (en) | Cd44-binding ligands | |
DE60041243D1 (de) | Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins | |
ATE182624T1 (de) | Phosphotyrosin phosphatase als neuer rezeptor-typ | |
DE60144021D1 (de) | Für zellzyklusproteine kodierende nukleinsäure und deren verwendung | |
BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
BR0016432A (pt) | Molécula de ácido nucleico isolada, vetor, célula hospedeira, descendentes, sementes ou material celular reproduzìvel, método de produção de um ou mais polipeptìdeo(s), tcmrp isolada, polipeptìdeo isolado, anticorpo, kit de teste, método para produzir um produto quìmico fino, produto quìmico fino, e, uso de um produto quìmico fino ou de polipeptìdeo(s). | |
ATE225942T1 (de) | Peptidereagenz zum nachweis von humanem cytomegalovirus (cmv) | |
DK0629238T3 (da) | Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi | |
DE59712771D1 (de) | Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung | |
HUP9801330A2 (hu) | Új PKA-kötő fehérjék és alkalmazásuk | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
ATE130757T1 (de) | Adhäsionsrezeptor für laminin und dessen verwendung. | |
DE69631624D1 (de) | Antikörper gegen menschliches restrictin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |